AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27939035 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction of heated egg powder
Number of subjects: 147
Study 27939035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 25806626 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Planning and Coping Planning strategies for medication adherence
Number of subjects: 115
Study 25806626 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 115
Study 24112026 — intervention group
Group type: EXPERIMENTAL
Intervention: milatuzumab 1.5 mg/kg, 4.0 mg/kg, 8.0 mg/kg, or 16.0 mg/kg administered twice weekly x 4
Number of subjects: 25
Study 24112026 — intervention group
Group type: EXPERIMENTAL
Intervention: milatuzumab
Number of subjects: 25
Study 21613429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 2069
Study 21613429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2069
Study 21613429 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemia
Number of subjects: 2069
Study 21613429 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoglobin
Number of subjects: 2069
Study 19918023 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon-oxygen mixture
Number of subjects: 0
Study 19918023 — intervention group
Group type: COMPARATOR
Intervention: Air-oxygen mixture (control group)
Number of subjects: 0
Study 19918023 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated CPB (pooled data from both groups)
Number of subjects: 0
Study 17209699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case‐managed program (NCM)
Number of subjects: 494
Study 17209699 — intervention group
Group type: COMPARATOR
Intervention: Usual care program
Number of subjects: 494
Study 15525782 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied over the left posterior parietal cortex (PPC)
Number of subjects: 0
Study 15525782 — intervention group
Group type: COMPARATOR
Intervention: Control group stimulated over the visual cortex
Number of subjects: 0
Study 11295628 — intervention group
Group type: COMPARATOR
Intervention: Soy protein intervention in men at high risk for recurrence, started within 4 months after surgery, followed for up to 2 years.
Number of subjects: 0
Study 11295628 — intervention group
Group type: COMPARATOR
Intervention: Soy protein intervention in men with PSA failure (PSA 0.1 to 2.0 ng/mL), treatment duration of 8 months.
Number of subjects: 0
Study 9642025 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfluent dysphasics reading aloud th-initial nonwords in sentential contexts
Number of subjects: 0
Study 9642025 — intervention group
Group type: COMPARATOR
Intervention: Normal control group reading aloud th-initial nonwords in sentential contexts
Number of subjects: 0
Study 7981558 — intervention group
Group type: EXPERIMENTAL
Intervention: LAD‐ORS (hydrolyzed lactalbumin with maltodextrin and sucrose)
Number of subjects: 74
Study 7981558 — intervention group
Group type: EXPERIMENTAL
Intervention: MS‐ORS (without hydrolyzed lactalbumin)
Number of subjects: 74
Study 7981558 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐ORS (standard glucose ORS)
Number of subjects: 74
Study 2645954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA, n = 26)
Number of subjects: 57
Study 2645954 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate followed by rescue with folinic acid (MTX + FA, n = 31)
Number of subjects: 57
Study 2645954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 57
Study 2645954 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate followed by rescue with folinic acid (MTX + FA)
Number of subjects: 57
Study 29357333 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL, 40 µg/mL of O₃‐O₂
Number of subjects: 60
Study 29357333 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL, 30 µg/mL of O₃‐O₂
Number of subjects: 60
Study 26659920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranio-cervical flexion training
Number of subjects: 28
Study 26659920 — intervention group
Group type: COMPARATOR
Intervention: Cervical proprioception training
Number of subjects: 28
Study 24172712 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS‐centred (Group A)
Number of subjects: 160
Study 24172712 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS‐centred (Group B)
Number of subjects: 160
Study 24172712 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS‐TBNA followed by EUS‐FNA (Group A)
Number of subjects: 160
Study 24172712 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS‐FNA followed by EBUS‐TBNA (Group B)
Number of subjects: 160
Study 24172712 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 160
Study 24330484 — intervention group
Group type: EXPERIMENTAL
Intervention: Legionnaires' disease
Number of subjects: 873
Study 20421817 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (cisplatin-vinorelbine-ifosfamide)
Number of subjects: 70
Study 20421817 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (high-dose single-drug ifosfamide)
Number of subjects: 70
Study 18387719 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02 vaccine on a 0, 1, and 3 month schedule
Number of subjects: 40
Study 18387719 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02 vaccine on a 0, 7, and 28 day schedule
Number of subjects: 40
Study 18387719 — intervention group
Group type: COMPARATOR
Intervention: Unimmunized infectivity controls
Number of subjects: 40
Study 16398379 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% intraoperative oxygen
Number of subjects: 95
Study 16398379 — intervention group
Group type: COMPARATOR
Intervention: 30% intraoperative oxygen
Number of subjects: 95
Study 12025912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxerutins (2 g/day for grade I CVI, 3 g/day for grade II CVI in the first 2 weeks; then 1 g/day for grade I CVI, 2 g/day for grade II CVI in the following 2 weeks)
Number of subjects: 60
Study 12025912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxerutins
Number of subjects: 60
Study 12025912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10428191 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (up to 2.0 mg/d) for 6 weeks
Number of subjects: 21
Study 10428191 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 21
Study 8932560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 21
Study 8932560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 1680760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 10
Study 1680760 — intervention group
Group type: COMPARATOR
Intervention: Loratadine 10 mg
Number of subjects: 10
Study 1680760 — intervention group
Group type: COMPARATOR
Intervention: Loratadine 40 mg
Number of subjects: 10
Study 7314868 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative long time anticoagulation
Number of subjects: 0
Study 7314868 — intervention group
Group type: COMPARATOR
Intervention: No postoperative anticoagulation (control)
Number of subjects: 0
Study 7314868 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative long time anticoagulation in femoral reconstructions
Number of subjects: 0
Study 7314868 — intervention group
Group type: COMPARATOR
Intervention: No postoperative anticoagulation in femoral reconstructions (control)
Number of subjects: 0
Study 31325466 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (SDF) solution
Number of subjects: 194
Study 31325466 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tonic water)
Number of subjects: 194
Study 31325466 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SDF and placebo groups
Number of subjects: 194
Study 27593794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided caudal epidural steroid injection
Number of subjects: 30
Study 27593794 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided caudal epidural steroid injection
Number of subjects: 30
Study 26099206 — intervention group
Group type: EXPERIMENTAL
Intervention: MWM and exercise/hot pack (n = 22)
Number of subjects: 44
Study 26099206 — intervention group
Group type: COMPARATOR
Intervention: exercise/hot pack alone (n = 22)
Number of subjects: 44
Study 24315625 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant anthracycline-based chemotherapy combined with taxanes
Number of subjects: 4996
Study 21590327 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg
Number of subjects: 365
Study 21590327 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 365
Study 18495465 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg-based diet (12 eggs.week(‐1))
Number of subjects: 12
Study 18495465 — intervention group
Group type: COMPARATOR
Intervention: No-egg diet (0 eggs.week(‐1))
Number of subjects: 12
Study 17545758 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Group 1)
Number of subjects: 54
Study 17545758 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (Group 2)
Number of subjects: 54
Study 16359206 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track recovery program
Number of subjects: 30
Study 16359206 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control)
Number of subjects: 30
Study 12056851 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized WOMAC 3.0 OA Index
Number of subjects: 50
Study 12056851 — intervention group
Group type: COMPARATOR
Intervention: Paper WOMAC 3.0 OA Index
Number of subjects: 50
Study 9856712 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 126
Study 9856712 — intervention group
Group type: COMPARATOR
Intervention: Regularly administered intramuscular injections of morphine
Number of subjects: 126
Study 7832132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nicorandil 1.5 mg in the left coronary artery
Number of subjects: 30
Study 7832132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nicorandil 1.0 mg in the right coronary artery
Number of subjects: 30
Study 7832132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nicorandil (various doses)
Number of subjects: 30
Study 7832132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nicorandil
Number of subjects: 30
Study 2121486 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 0
Study 2121486 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 0
Study 2121486 — intervention group
Group type: EXPERIMENTAL
Intervention: t-PA
Number of subjects: 0
Study 2121486 — intervention group
Group type: COMPARATOR
Intervention: Genentech t-PA
Number of subjects: 0
Study 7192456 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 to 360 mg daily, mean 198 +/- 80 mg) for 3.5 weeks to 7 months (averaging 3 months)
Number of subjects: 20
Study 7192456 — intervention group
Group type: EXPERIMENTAL
Intervention: Transaortal subvalvular myectomy after 1 week to 28 months (averaging 7.5 months)
Number of subjects: 20
Study 31647854 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin for nebulization
Number of subjects: 206
Study 31647854 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium HandiHaler® DPI
Number of subjects: 206
Study 30559343 — intervention group
Group type: EXPERIMENTAL
Intervention: Papacarie gel (caries removal with the chemical‐mechanical method)
Number of subjects: 24
Study 30559343 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (drilling)
Number of subjects: 24
Study 30559343 — intervention group
Group type: EXPERIMENTAL
Intervention: Drill + Papacarie
Number of subjects: 24
Study 30559343 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 24
Study 30559343 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate, consultation duration, and number of restorations
Number of subjects: 24
Study 26054549 — intervention group
Group type: EXPERIMENTAL
Intervention: Reimbursement of up to 50 US dollars for purchased vegetables (treatment group, n=69)
Number of subjects: 144
Study 26054549 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=69)
Number of subjects: 144
Study 24365793 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (Control)
Number of subjects: 307
Study 24365793 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral NAC + i.v. saline
Number of subjects: 307
Study 24365793 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. NAC + i.v. saline
Number of subjects: 307
Study 22151564 — intervention group
Group type: EXPERIMENTAL
Intervention: SWIFT Cast (soft scotch ankle-foot cast)
Number of subjects: 120
Study 22151564 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 120
Study 19762222 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (160/4.5 microg bid and as needed)
Number of subjects: 7855
Study 19762222 — intervention group
Group type: COMPARATOR
Intervention: Conventional best practice (CBP) (ICS or ICS/LABA+/−other agents at an approved dose plus as-needed SABA)
Number of subjects: 7855
Study 17449081 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular patterns
Number of subjects: 0
Study 17449081 — intervention group
Group type: COMPARATOR
Intervention: Random patterns
Number of subjects: 0
Study 15513315 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 27
Study 15513315 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrafiltration
Number of subjects: 27
Study 11401008 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg EMD
Number of subjects: 10
Study 11401008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9482137 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg once daily)
Number of subjects: 69
Study 9482137 — intervention group
Group type: COMPARATOR
Intervention: Captopril (50 mg twice daily)
Number of subjects: 69
Study 9482137 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 69
Study 9482137 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 69
Study 7989400 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose methylprednisolone; short course; dosage not specified; duration not specified.
Number of subjects: 0
Study 2658841 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day Tamoxifen
Number of subjects: 34
Study 2658841 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/day Tamoxifen
Number of subjects: 34
Study 2658841 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation to 40 mg/day after 20 mg/day
Number of subjects: 34
Study 4157346 — intervention group
Group type: EXPERIMENTAL
Intervention: One daily intramuscular injection of 160 mg of gentamicin
Number of subjects: 21
Study 4157346 — intervention group
Group type: COMPARATOR
Intervention: Three injections daily (60 or 80 mg every 8 h)
Number of subjects: 21
Study 4157346 — intervention group
Group type: EXPERIMENTAL
Intervention: One daily injection of gentamicin
Number of subjects: 21
Study 4157346 — intervention group
Group type: COMPARATOR
Intervention: Three injections daily
Number of subjects: 21
Study 31560216 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month dual antiplatelet therapy (DAPT)
Number of subjects: 0
Study 31560216 — intervention group
Group type: COMPARATOR
Intervention: 12-month dual antiplatelet therapy (DAPT)
Number of subjects: 0
Study 29233097 — intervention group
Group type: EXPERIMENTAL
Intervention: DE-REACH intervention (12 individual two-weekly sessions, 9 at home, 3 via telephone)
Number of subjects: 92
Study 29233097 — intervention group
Group type: EXPERIMENTAL
Intervention: DE-REACH intervention
Number of subjects: 92
Study 29233097 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 92
Study 25147363 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant hand (test 1)
Number of subjects: 41
Study 25147363 — intervention group
Group type: COMPARATOR
Intervention: Non-dominant hand (test 2)
Number of subjects: 41
Study 23507477 — intervention group
Group type: EXPERIMENTAL
Intervention: HAM-RS2 (48 g dietary fibre from high-amylose maize type 2 resistant starch)
Number of subjects: 30
Study 23507477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23507477 — intervention group
Group type: EXPERIMENTAL
Intervention: HAM-RS2
Number of subjects: 30
Study 22114703 — intervention group
Group type: EXPERIMENTAL
Intervention: Regents Academy program for at-risk students during the normal school day and year.
Number of subjects: 0
Study 22114703 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified in detail).
Number of subjects: 0
Study 19901711 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - Enoxaparin sodium 40mg/d
Number of subjects: 75
Study 19901711 — intervention group
Group type: COMPARATOR
Intervention: Control - Long compression stockings (CS)
Number of subjects: 75
Study 16408299 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 51
Study 16408299 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 51
Study 12498603 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO) treatment started within 2 weeks after birth until soft palate closure at 12 months of age.
Number of subjects: 2
Study 12498603 — intervention group
Group type: COMPARATOR
Intervention: Non-infant orthopedics (non-IO) treatment with extra check-ups at 6 weeks and before and after lip repair and soft palate closure.
Number of subjects: 2
Study 17170610 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ combination therapy (150 mg/12.5 mg, titrated to 300 mg/25 mg at week 1)
Number of subjects: 737
Study 17170610 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan monotherapy (150 mg, titrated to 300 mg at week 1)
Number of subjects: 737
Study 17170610 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ combination therapy
Number of subjects: 737
Study 17170610 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan monotherapy
Number of subjects: 737
Study 10472868 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (10- or 20-mg patch)
Number of subjects: 245
Study 10472868 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ritodrine
Number of subjects: 245
Study 8734594 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosin-coated glass
Number of subjects: 10
Study 8734594 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass
Number of subjects: 10
Study 8734594 — intervention group
Group type: EXPERIMENTAL
Intervention: Satin-finished aluminum
Number of subjects: 10
Study 8734594 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly-vinyl chloride (PVC) plastic
Number of subjects: 10
Study 8734594 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon
Number of subjects: 10
Study 8734594 — intervention group
Group type: EXPERIMENTAL
Intervention: Nyloprint (polyamide plastic)
Number of subjects: 10
Study 8734594 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective estimates of friction
Number of subjects: 10
Study 1902238 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (333 mg administered orally every 8 hr for 4 days)
Number of subjects: 12
Study 1902238 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (glyburide 5 mg administered on day 4 of each study period)
Number of subjects: 12
Study 7116714 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized simulated patient problems
Number of subjects: 37
Study 31563504 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair using a transosseous knotless anchor (ATOK)
Number of subjects: 15
Study 31103114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation® (FM)
Number of subjects: 29
Study 31103114 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal training protocols and standard medical care)
Number of subjects: 29
Study 28736381 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril treatment (experimental group)
Number of subjects: 210
Study 28736381 — intervention group
Group type: COMPARATOR
Intervention: Captopril treatment (control group)
Number of subjects: 210
Study 25734566 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliadin
Number of subjects: 23
Study 25734566 — intervention group
Group type: COMPARATOR
Intervention: Media (control)
Number of subjects: 23
Study 24827134 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg once daily
Number of subjects: 207
Study 24827134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 24827134 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg once daily (after adjustment for baseline characteristics)
Number of subjects: 207
Study 24827134 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg once daily (exploratory analysis)
Number of subjects: 207
Study 22625844 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention (two face-to-face and four telephonic sessions)
Number of subjects: 928
Study 22625844 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention
Number of subjects: 928
Study 22625844 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 928
Study 19741011 — intervention group
Group type: COMPARATOR
Intervention: MTX (0.3 mg/kg/week, maximum of 20 mg/week, without escalating dose regimen)
Number of subjects: 65
Study 19741011 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with MTX and ADA (40 mg eow)
Number of subjects: 65
Study 19741011 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX and ADA combination therapy
Number of subjects: 65
Study 19741011 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 65
Study 17971594 — intervention group
Group type: EXPERIMENTAL
Intervention: ATA + TOR (Atamestane 500 mg + Toremifene 60 mg)
Number of subjects: 865
Study 17971594 — intervention group
Group type: COMPARATOR
Intervention: LET (Letrozole 2.5 mg)
Number of subjects: 865
Study 17971594 — intervention group
Group type: EXPERIMENTAL
Intervention: ATA + TOR
Number of subjects: 865
Study 17971594 — intervention group
Group type: COMPARATOR
Intervention: LET
Number of subjects: 865